| abstract |
1. A polypeptide containing a binding domain capable of binding to an epitope of the human CD3ε (epsilon) chain and a non-chimpanzee primate, wherein said epitope is a part of the amino acid sequence included in the group consisting of SEQ ID NO: 2, 4, 6 or 8.! 2. The polypeptide according to claim 1, where the specified binding domain capable of binding to the epitope of the CD3ε (epsilon) chain of humans and non-chimpanzee primates is of human origin. ! 3. The polypeptide according to any one of claims 1 or 2, wherein the polypeptide comprises a first binding domain capable of binding to an epitope of a human CD3ε chain and a non-chimpanzee primate, and a second binding domain capable of binding to a cell surface antigen. ! 4. The polypeptide according to claim 3, where the second binding domain binds to the cell surface antigen of a human and a non-chimpanzee primate. ! 5. The polypeptide according to any one of claims 1 to 4, where the first binding domain capable of binding to an epitope of a human CD3ε chain and a non-chimpanzee primate contains a VL region (light chain variable region) containing a CDR (hypervariable region) - L-1, CDR-L2 and CDR-L3 selected from:! (a) CDR-L1, as presented in SEQ ID NO: 27, CDR-L2, as presented in SEQ ID NO: 28, and CDR-L3, as presented in SEQ ID NO: 29; ! (b) CDR-L1, as presented in SEQ ID NO: 117, CDR-L2, as presented in SEQ ID NO: 118, and CDR-L3, as presented in SEQ ID NO: 119; and! (c) CDR-L1, as presented in SEQ ID NO: 153, CDR-L2, as presented in SEQ ID NO: 154, and CDR-L3, as presented in SEQ ID NO: 155.! 6. The polypeptide according to any one of claims 1 to 4, where the first binding domain capable of binding to the epitope of the human CD3ε chain and a non-chimpanzee primate contains the VH region (variable region |